This paper is in the following e-collection/theme issue:

Big Data (240)

Published on in Vol 4, No 4 (2016): Oct-Dec

Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data

Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data

Population Analysis of Adverse Events in Different Age Groups Using Big Clinical Trials Data

Authors of this article:

Jake Luo1, 2, 3 Author Orcid Image ;   Christina Eldredge2, 4 Author Orcid Image ;   Chi C Cho3, 5 Author Orcid Image ;   Ron A Cisler1, 2, 3, 6, 7, 8 Author Orcid Image
Article Authors Cited by (22) Tweetations (6) Metrics

Journals

  1. Ng H, Rosenbult C, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opinion on Drug Safety 2020;19(9):1069 View
  2. Woods J, Saxena M, Nagamine T, Howell R, Criscitelli T, Gorenstein S, M. Gillette B. The Future of Data‐Driven Wound Care. AORN Journal 2018;107(4):455 View
  3. Lee H, Kim J, Choe Y, Shin J. Safety Surveillance of Pneumococcal Vaccine Using Three Algorithms: Disproportionality Methods, Empirical Bayes Geometric Mean, and Tree-Based Scan Statistic. Vaccines 2020;8(2):242 View
  4. Hanlon P, Corcoran N, Rughani G, Shah A, Mair F, Guthrie B, Renton J, McAllister D. Observed and expected serious adverse event rates in randomised clinical trials for hypertension: an observational study comparing trials that do and do not focus on older people. The Lancet Healthy Longevity 2021;2(7):e398 View
  5. Moon S, Kim J, Kim D, Lee K, Reines E, Lee M, Park Y. Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea. Frontiers in Psychiatry 2023;14 View
  6. Peng H, Zhang R, Dou Y, Yang R, Zhang J, Yu P. Reinforced Neighborhood Selection Guided Multi-Relational Graph Neural Networks. ACM Transactions on Information Systems 2022;40(4):1 View
  7. Mathes T, Mann N, Thürmann P, Sönnichsen A, Pieper D. Assessing the quality of evidence on safety: specifications for application and suggestions for adaptions of the GRADE-criteria in the context of preparing a list of potentially inappropriate medications for older adults. BMC Medical Research Methodology 2022;22(1) View
  8. Hong B, Lee H, Rhee H, Kim J, Jeon H, Kim S, Choi N, Jung S, Shin J. The Different Safety Signals on Influenza Vaccine in Adults and the Elderly: A Nationwide Post-Marketing Surveillance Study from 2005 to 2019. Drug Targets and Therapeutics 2022;1(1):51 View
  9. Omolo B, Njuho P. Adverse Event Risk Assessment on Patients Receiving Combination Antiretroviral Therapy in South Africa. International Journal of Statistics in Medical Research 2020;9:10 View
  10. Hsieh S, Chang Y, Yao Z, Yang M, Yang C. The effect of age and resilience on the dose–response function between the number of adversity factors and subjective well-being. Frontiers in Psychology 2024;15 View
  11. Shetty G, Shah N, Arenja A, Jacobs K, Soer R. Occupation-based demographic, clinical, and psychological presentation of spine pain: A retrospective analysis of 71,727 patients from urban India. Work 2024;78(1):181 View
  12. Thomas J, Hanna F. ‘COVID-19 vaccines are safe’: however, the issues of vaccine equity and data equity remain. Critical Public Health 2024;34(1):1 View
  13. Dandurand C, Laghaei P, Fisher C, Ailon T, Dvorak M, Kwon B, Dea N, Charest-Morin R, Paquette S, Street J. Out-of-hours emergent surgery for degenerative spinal disease in Canada: a retrospective cohort study from a national registry. The Lancet Regional Health - Americas 2024;36:100816 View
  14. Jones M, Clifford B, Stamatakis E, Gibbs M. Response to Comment on “Exercise Snacks and Other Forms of Intermittent Physical Activity for Improving Health in Adults and Older Adults: A Scoping Review of Epidemiological, Experimental and Qualitative Studies”. Sports Medicine 2024;54(8):2205 View
  15. Tokede B, Yansane A, Walji M, Rindal D, Worley D, White J, Kalenderian E. The Nature of Adverse Events in Dentistry. Journal of Patient Safety 2024;20(7):454 View
  16. Lukka P, Tang W, Hammarstedt A, Conrad T, Heijer M, Karlsson C, Boulton D. Racial Comparison of the Pharmacokinetics and Safety of Fixed-dose Combination of Dapagliflozin/Sitagliptin in Western and Korean Healthy Adults. Clinical Therapeutics 2024;46(9):717 View
  17. Shiraishi C, Kato H, Ogura T, Iwamoto T. Association between age and onset of daptomycin-induced adverse events using the U.S. food and drug administration adverse event reporting system. Journal of Infection and Chemotherapy 2024 View
  18. Dmukauskas M, Cioffi G, Waite K, Mammoser A, Sloan A, Ma P, Barnholtz-Sloan J. Sex Difference in Disease-Related Adverse Events Post-Diagnosis of Lung Cancer Brain Metastases in Medicare Individuals ≥ 66 Years of Age. Cancers 2024;16(17):2986 View

Books/Policy Documents

  1. Cao Y, Peng H, Yu P. Advances in Knowledge Discovery and Data Mining. View
  2. Streiner D. Integrity of Scientific Research. View